AB0799 REAL-WORLD EXPERIENCE OF SECUKINUMAB FOR PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT.

Background:Evidence on the efficacy of biologics in the treatment of psoriatic arthritis (PsA) patients with axial manifestations affecting 30-70% of PsA patients is limited. Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active PsA and ankylosing spondylitis.Objectives:This study aims to analyze the experience of using SEC for PsA patients with axial involvement in real-world setting.Methods:Multicentric observational, longitudinal, retrospective study conducted in a tertiary hospital between January 2016 and December 2019. Patients with PsA (CASPAR criteria) and clinical and/or image diagnosis of axial involvement receiving at least one dose of SEC were included. Patients with non-pathological sacroiliacs x-ray and MRI had to have spinal pain VAS ≥4/10 after failure to NSAIDs, prior to the onset of SEC, to be included. Medical records were reviewed to collect demographic and clinical data, features of PsA (manifestations, treatments and activity assessment). Descriptive statistics and then a comparative analysis with the Studentt-test to analyze the effectiveness of SEC were performed.Results:Of 98 PsA patients treated with SEC, 58 (59.2%) had axial involvement, of which 41 (71%) female. Mean age was 54 y.o (SD 10) and average duration of the disease was 10 years (SD 8). All 58 patients had peripheral disease (33% joint erosions), 55 (95%) had psoriasis, 20 (34%) showed dactilitis and 39 (67%) had enthesitis. Sacroiliacs x-ray was damaged in 38 (66%) patients (grade I-IV) and 23 (40%) pathological MRI, with HLAB27+ at 8 (14%) patients. Average BMI was 29 (SD 8), with an obesity rate of 33% (19 pt). Observed comorbidities were hypertension (27 pt, 47%), diabetes mellitus (6 pt, 10%), dyslipidemia (23 pt, 40%), active smoking (18 pt, 31%) and malignancy (6 pt, 10%). Regarding previous treatments, 90% had received cDMARDs, particularly methotrexate (86%) and 40 (69%) had been exposed to at least one bDMARD (15 pt to one, 9 to two, 6 to three and 10 to four or more). 7 patients were on 300 mg dose and 51 patients on 150 mg dose (dose escalation to 300 mg was performed in 16 patients and 44% respond and maintain SEC). Average drug survival time was 1.4 (SD 1) years. At 6 months of SEC therapy, tender and swollen joint count, spinal pain VAS, CRP, ASDAS-CRP and DAPSA had significantly decreased (Table 1). 29 (50%) patients suspended SEC during follow-up due to primary ineffectiveness (8), secondary ineffectiveness (16), adverse events (3), latex allergy (1) and remission (1). Adverse events do not differ from those reported in clinical trials.Table 1.Disease activity assessment at 6 months of secukinumab therapy.Baseline6 months after SECMean differenceP valueSJC4,8±5,41,9±3,1-2,8 (IC95% -3,9 a -1,7)p<0,0001TJC7,7±5,83,9±4,1-3,8 (IC95% -5,1 a -2,4)p<0,0001Spinal pVAS6,1±3,24,2±2,9-1,9 (IC95% -2,4 a -1,4)p<0,0001CRP (mg/L)7,7±9,94,9±5,9-2,9 (IC95% -4,5 a -1,2)p=0,0009ASDAS-CRP2,5±1,91,8±1,3-0,7 (IC95% -0,9 a -0,4)p<0,0001DAPSA27,7±12,116,7±10,4-11 (IC95% -15,3 a -6,8)p<0,0001SJC: swollen joint count, TJC: tender joint count, Spinal pVAS: spinal pain visual analog scale, CRP: C-reactive protein, SEC: secukinumab.Conclusion:Secukinumab in real-world setting provided improvements in the axial and peripheral manifestations of PsA, using both the 150 mg and 300 mg doses.Disclosure of Interests:MARIA MARTIN LOPEZ: None declared, Beatriz Joven-Ibáñez Speakers bureau: Abbvie, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, José Luis Pablos: None declared

Download Full-text

AB0649 REAL WORLD EFFICACY OF SECUKINUMAB: A SINGLE CENTRE EXPERIENCE

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.4311 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1619-1620

Author(s):

G. Kasavkar ◽

T. Blake ◽

N. Gullick

Keyword(s):

Clinical Trial ◽

Psoriatic Arthritis ◽

Ankylosing Spondylitis ◽

Adverse Events ◽

Real World ◽

Certolizumab Pegol ◽

Tender Joint Count ◽

Inadequate Response ◽

Technology Appraisal ◽

New Onset

Background:Secukinumab was approved by NICE for patients with active Ankylosing Spondylitis and Psoriatic Arthritis in 2017. Clinical trial data suggests secukinumab is a useful treatment option in both conditions, but often real world experience differs greatly from clinical trial results. In addition, patients with more refractory disease are often excluded from clinical trials.Objectives:To assess the response to secukinumab in patients with seronegative spondyloarthropathy receiving treatment at University Hospital Coventry and WarwickshireMethods:Patients starting secukinumab at UHCW were identified from the Blueteq funding database. Medical notes were reviewed retrospectively to assess response rates using BASDAI responses in Ankylosing spondylitis and PsARC responses in PsA. Patients who had previously had inadequate response to TNF inhibitors (PsA only) and severe psoriasis received 300mg secukinumab monthly; the remainder were prescribed 150mg monthly.Results:146 patients commenced secukinumab between June 2017 and January 2020 and had outcome data recorded. 73 patients (50%) had received previous biologic agents prior to secukinumab exposure. Patients with Ankylosing spondylitis had high BASDAI (6.8±1.4) and spinal pain (7.5±1.4). 48 patients had an initial response to treatment as per outcome measures done before and after Secukinumab inception. Secukinumab was effective in 89 patients (94%), and 87 (91%) continued treatment.In psoriatic arthritis, despite high levels of activity at baseline (mean tender joint count 10±8; swollen joint count 6±3) and 65% prior biologic exposure; high rates of response were seen. The majority of patients have continued treatment. Secukinumab was well tolerated in both patient groups with low rates of discontinuation due to adverse events (8 patients, 5%). Adverse events included recurrent infection (3), rash (1), mouth ulcers (1), vertigo (1), new onset cancer (1) and new onset Crohn’s (1) although rates were low overall. Patients with pre-existing uveitis did not develop exacerbations but low numbers of patients with prior uveitis were treated.PsA (n=51)AS (n=95)Age in years, mean (SD)53 (13)49(12)Male sex, n (%)21 (41)62 (65)Disease duration in years, mean (SD)8 (8)10.9 (9.2)Previous biologic exposure, n (%)30 (65)43 (48)Number of prior biologics, median (range)1 (1-4)1 (1-4)Responder, n (%)37 (72)*89 (93)Discontinuation, n(%)12 (24)8 (8.5)Adverse events62Lack of efficacy64Other02*Response could not be assessed in 3/51 PsA patients due to insufficient clinical data; these patients have been recorded as non respondersConclusion:Secukinumab demonstrates high levels of efficacy even in a cohort of patients with longstanding PSA and AS with high rates of inadequate responses to other biologics.Secukinumab is well tolerated with low rates of discontinuation due to adverse events.References:Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs Technology appraisal guidance [TA445]Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors Technology appraisal guidance [TA407]Disclosure of Interests:None declared

Download Full-text

EP40 Real world efficacy of secukinumab: a single centre experience

Rheumatology ◽

10.1093/rheumatology/keaa109.039 ◽

2020 ◽

Vol 59 (Supplement_2) ◽

Author(s):

Tim Blake ◽

Nicola J Gullick

Keyword(s):

Clinical Trial ◽

Psoriatic Arthritis ◽

Ankylosing Spondylitis ◽

Adverse Events ◽

Real World ◽

Response To Treatment ◽

Tender Joint Count ◽

Inadequate Response ◽

Tender Joint ◽

New Onset

Abstract Background Secukinumab was approved by NICE for patients with active ankylosing spondylitis and psoriatic arthritis in 2017. Clinical trial data suggests secukinumab is a useful treatment option in both conditions, but often real world experience differs greatly from clinical trial results. In addition, patients with more refractory disease are often excluded from clinical trials. Methods Patients starting secukinumab at UHCW were identified from the Blueteq funding database. Medical notes were reviewed retrospectively to assess response rates using BASDAI responses in Ankylosing spondylitis and PsARC responses in PsA. Patients who had previously had inadequate response to TNF inhibitors (PsA only) and severe psoriasis received 300mg secukinumab monthly; the remainder were prescribed 150mg monthly. Results 113 patients commenced secukinumab between June 2017 and April 2019 and had outcome data recorded. 59 patients (52%) had received previous biologic agents prior to secukinumab exposure. Patients with ankylosing spondylitis had high BASDAI (6.91.4) and spinal pain (7.71.4). 38 patients had an initial response to treatment. Secukinumab was effective in 39 patients (63%), and 37 (62%) continued treatment. In psoriatic arthritis, despite high levels of activity at baseline (mean tender joint count 10 8; swollen joint count 63, and 65% prior biologic exposure, high rates of response were seen. The majority of patients have continued treatment. Secukinumab was well tolerated in both patient groups with low rates of discontinuation due to adverse events (11 patients, 9%). Adverse events included recurrent infection (6), rash (1), mouth ulcers (1), vertigo (1), new onset cancer (1) and new onset Crohn’s (1) although rates were low overall. Patients with pre-existing uveitis did not develop exacerbations but low numbers of patients with prior uveitis were treated. Conclusion Secukinumab demonstrates high levels of efficacy even in a cohort of patients with longstanding PSA and AS with high rates of inadequate responses to other biologics. Secukinumab is well tolerated with low rates of discontinuation due to adverse events. Disclosures: T. Blake: None. N.J. Gullick: Honoraria; NG has received Honoraria from Abbvie, Eli Lilly, Novartis, UCB. Grants/research support; NG has received funding for research from Abbvie and Novartis.

Download Full-text

267-OR: Reduction in Self-Reported Adverse Events Related to Severe Hypoglycemia in Individuals Using a Predictive Low Glucose System: Results from a Real-World Setting

Diabetes ◽

10.2337/db20-267-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 267-OR

Author(s):

HARSIMRAN SINGH ◽

MICHELLE L. MANNING ◽

MOLLY MCELWEE-MALLOY ◽

STEPHANIE HABIF

Keyword(s):

Adverse Events ◽

Real World ◽

Severe Hypoglycemia ◽

Real World Setting ◽

Glucose System ◽

Low Glucose

Download Full-text

Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting

Giornale Italiano di Dermatologia e Venereologia ◽

10.23736/s0392-0488.18.06095-9 ◽

2019 ◽

Vol 154 (2) ◽

Cited By ~ 4

Author(s):

Giulia Radi ◽

Annamaria Campanati ◽

Federico Diotallevi ◽

Elisa Molinelli ◽

Anna Offidani

Keyword(s):

Psoriatic Arthritis ◽

Real World ◽

Skin Involvement ◽

Preliminary Results ◽

Results Of Treatment ◽

Real World Setting

Download Full-text

FRI0009 Infliximab in the treatment of rheumatoid arthritis (ra): referral patterns, response to treatment, and adverse events in a real world setting

10.1136/annrheumdis-2001.1138 ◽

2001 ◽

Author(s):

Y Yazici ◽

D Erkan ◽

I Kulman ◽

L Leff ◽

J Markenson ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Adverse Events ◽

Real World ◽

Response To Treatment ◽

Referral Patterns ◽

Real World Setting

Download Full-text

Applications of Wearable Technology in a Real-Life Setting in People with Knee Osteoarthritis: A Systematic Scoping Review

Journal of Clinical Medicine ◽

10.3390/jcm10235645 ◽

2021 ◽

Vol 10 (23) ◽

pp. 5645

Author(s):

Tomasz Cudejko ◽

Kate Button ◽

Jake Willott ◽

Mohammad Al-Amri

Keyword(s):

Knee Osteoarthritis ◽

Real World ◽

Real Life ◽

Wearable Technology ◽

Physical Activity Assessment ◽

Activity Assessment ◽

Real World Setting ◽

Real Life Setting ◽

Clinical Potential ◽

Provision Of Care

With the growing number of people affected by osteoarthritis, wearable technology may enable the provision of care outside a traditional clinical setting and thus transform how healthcare is delivered for this patient group. Here, we mapped the available empirical evidence on the utilization of wearable technology in a real-world setting in people with knee osteoarthritis. From an analysis of 68 studies, we found that the use of accelerometers for physical activity assessment is the most prevalent mode of use of wearable technology in this population. We identify low technical complexity and cost, ability to connect with a healthcare professional, and consistency in the analysis of the data as the most critical facilitators for the feasibility of using wearable technology in a real-world setting. To fully realize the clinical potential of wearable technology for people with knee osteoarthritis, this review highlights the need for more research employing wearables for information sharing and treatment, increased inter-study consistency through standardization and improved reporting, and increased representation of vulnerable populations.

Download Full-text

Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies in a real-world setting.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e24072 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e24072-e24072

Author(s):

Jun Ma ◽

Huiqiang Huang ◽

Peifen Fu ◽

Nong Xu ◽

Chenyu Mao ◽

...

Keyword(s):

Adverse Events ◽

Real World ◽

Study Drug ◽

Secondary Prophylaxis ◽

Chemotherapy Cycle ◽

Breast Cancer Patients ◽

Continuous Administration ◽

Real World Setting ◽

Grade 3 ◽

Long Acting

e24072 Background: The prophylaxis of neutropenia has been evolving from short acting granulocyte colony-stimulating factors (G-CSFs) to long acting G-CSFs. The safety and effectiveness of long acting G-CSF in a real-world setting were still lacking. Methods: We performed a multi-center, non-interventional, real-world study to explore the tolerability and effectiveness of mecapegfilgrastim. Different prophylactic strategy (primary or secondary prophylaxis) were compared. The effect of mecapegfilgrastim by means of continuous administration was also explored. Results: This study included 638 patients who had complete the study from May 2019 to November 15, 2020. About half of the participants were breast cancer patients. The mean age of the patients were 56 years. The most frequently reported adverse event possibly related to study drug was white blood cell increase (6.2 %). No unexpected adverse events were reported. Overall, thirty-six (5.6 %) patients experienced grade ≥ 3 neutropenia in chemotherapy cycle one. The patients in the primary and secondary prophylaxis subgroups had incidence of grade ≥ 3 neutropenia of 4.3 % and 9.2 % in chemotherapy cycle one respectively. There was a decreasing trend of neutropenia from cycle one to cycle four when mecapegfilgrastim were administrated continuously. Conclusions: The mecapegfilgrastim was well tolerable and no unexpected adverse events were observed in real-world setting. Primary prophylaxis using mecapegfilgrastim had lower incidence of neutropenia than secondary usage.

Download Full-text